Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Wart Clear all
Completed Phase 3 Interventional

Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts

NCT00449982
View directory record Official record
Conditions
Condylomata Acuminata
Interventions
Polyphenon E Ointment 10%, Polyphenon E Ointment 15%
Drug
Lead sponsor
MediGene
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
6
States / cities
Davis, San Diego, California • Denver, Colorado • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2007 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Intralesional Vitamin D Injection for Treatment of Common Warts

NCT04278573
View directory record Official record
Conditions
Warts
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Stephen P. Merry
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment

NCT02147353
View directory record Official record
Conditions
External Genital Warts
Interventions
Sinecatechins 15% Ointment, Cryotherapy alone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NCT00967785
View directory record Official record
Conditions
Leukopenia, Neutropenia, Infections, Warts, Myelokathexis
Interventions
Mozobil (TM)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Not applicable Interventional

Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy

NCT01609530
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
Liquid Nitrogen Cryotherapy, Pulsed 1064nm Nd:YAG
Procedure
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nanopulse Efficacy Study for the Treatment of Common Warts

NCT02650466
View directory record Official record
Conditions
Common Warts
Interventions
Nanopulse System
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 3 Interventional

Cold Atmospheric Plasma Device Extension Study

NCT05937672
View directory record Official record
Conditions
Verruca Vulgaris, Molluscum Contagiosum
Interventions
Floating electrode-dielectric barrier device (FE-DBD) cold atmospheric plasma (CAP)
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
4 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

NCT00499967
View directory record Official record
Conditions
Genital Warts
Interventions
GS-9191 ointment, GS-9191, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
25
States / cities
Tucson, Arizona • Beverly Hills, California • Mission Viejo, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2009 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intralesional HPV Vaccine for Condylomata

NCT05087849
View directory record Official record
Conditions
Human Papilloma Virus, Warts, Warts, Genital, Condyloma, Condylomata Acuminata
Interventions
nonavalent human papillomavirus vaccine
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common Warts

NCT04738734
View directory record Official record
Conditions
Warts, Warts Hand, Verruca
Interventions
CellFX System Device, Cryosurgery Liquid Nitrogen Sprayer
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
22 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Scottsdale, Arizona • Beverly Hills, California • Greenwood Village, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

NCT02748902
View directory record Official record
Conditions
Verruca Vulgaris, Common Warts
Interventions
ingenol mebutate 0.05% gel
Drug
Lead sponsor
Neal D. Bhatia, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands

NCT00973856
View directory record Official record
Conditions
Papillomavirus Infections, Warts, Condylomata Acuminata, Epidermodysplasia Verruciformis
Interventions
PURELL VF481, Placebo Solution
Other
Lead sponsor
Cleveland Clinic Akron General
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 1 Interventional Results available

Study With Candida Antigen for Treatment of Warts

NCT00569231
View directory record Official record
Conditions
Warts, HPV
Interventions
Candida Antigen
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2011 · Synced Jul 22, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Alternate Dosing Schedules Study for HPV Vaccine (ADS)

NCT02280642
View directory record Official record
Conditions
Cervical Cancer, Genital Warts
Interventions
Both 2nd and 3rd doses on time, 2nd dose late and 3rd dose on time, 2nd dose on time and 3rd dose late, Both doses late
Biological
Lead sponsor
Duke University
Other
Eligibility
9 Years to 18 Years · Female only
Enrollment
331 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
3
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

ALC-919 For The Treatment Of Common Warts

NCT02483455
View directory record Official record
Conditions
Verruca Vulgaris
Interventions
2014-ALC-919-US, Vehicle-Control Topical Solution
Drug
Lead sponsor
Veloce BioPharma LLC
Industry
Eligibility
8 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Fort Washington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2016 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Candin Safety & Efficacy Study for the Treatment of Warts

NCT01757392
View directory record Official record
Conditions
Warts, Human Papilloma Virus
Interventions
Candida albicans Skin Test Antigen
Biological
Lead sponsor
Nielsen BioSciences, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Fort Smith, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

NCT03259620
View directory record Official record
Conditions
Cutaneous Common Warts
Interventions
CLS006, CLS006 Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
2 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Hot Springs, Arkansas • Oceanside, California • San Diego, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862
View directory record Official record
Conditions
Common Warts
Interventions
A-101 Solution 40, A-101 Solution 45, Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Common Warts

NCT01286441
View directory record Official record
Conditions
Common Warts
Interventions
10% EISO, Placebo, 20% EISO, 30% EISO
Drug
Lead sponsor
ViroXis Corporation
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
20
States / cities
Rogers, Arkansas • Fremont, California • Lomita, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

NCT02482428
View directory record Official record
Conditions
External Genital Warts
Interventions
Investigational Treatment, Aldara
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Arlington Heights, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

NCT03812510
View directory record Official record
Conditions
Common Wart
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
1 Year and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
46
States / cities
Mobile, Alabama • Glendale, Arizona • Fort Smith, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2 Interventional Results available

Cantharidin and Occlusion in Verruca Epithelium

NCT03487549
View directory record Official record
Conditions
Common Wart, Warts Hand, Warts, Papillomavirus Infections, DNA Virus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Virus Diseases, Tumor Virus Infections, Verruca Vulgaris, Verruca
Interventions
VP-102 Cantharidin, topical film forming solution
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
2 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

NCT02231879
View directory record Official record
Conditions
Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
Interventions
Plerixafor, G-CSF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Drug Therapy to Treat Minor Depression

NCT00048815
View directory record Official record
Conditions
Depression
Interventions
Citalopram, St. John's Wort, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Jul 22, 2026, 10:53 AM EDT